Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 8790869

    Renal cell carcinoma biomarkers

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8785373

    Agents capable of downregulating an MSF-A-dependent HIF-1alpha and use thereof in cancer treatment

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Tue Jul 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8785409

    Compounds having anti-adhesive effects on cancer cells

    The Board of Regents of the University of Texas System · Granted Tue Jul 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8779151

    Orally bioavailable caffeic acid related anticancer drugs

    The Board of Regents of the University of Texas System · Granted Tue Jul 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8778608

    CA9 gene single nucleotide polymorphisms predict prognosis and treatment response of metastatic renal cell carcinoma

    The Regents of the University of California · Granted Tue Jul 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8772238

    Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Jul 08 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8765935

    Nucleosides with antiviral and anticancer activity

    Regents of the University of Minnesota · Granted Tue Jul 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8759006

    PSCA: prostate stem cell antigen and distinguishing androgen receptor negative prostate cancer from benign prostatic hyperplasia

    The Regents of the University of California · Granted Tue Jun 24 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8754124

    Oligo-benzamide compounds and their use in treating cancers

    The Board of Regents of the University of Texas System · Granted Tue Jun 17 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8754046

    MHC class II restricted T cell epitopes from the cancer anitgen, NY ESO-1

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 17 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8748114

    ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Jun 10 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8742141

    Inhibition and treatment of prostate cancer metastasis

    Northwestern University · Granted Tue Jun 03 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8741306

    Kidney specific tumor vaccine directed against kidney tumor antigen G-250

    The Regents of the University of California · Granted Tue Jun 03 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8741315

    Methods of treating tumors in immune-privileged sites

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Tue Jun 03 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8734799

    Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer

    The Regents of the University of California · Granted Tue May 27 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8735075

    Cancer screening by detection of ultrastructural and molecular markers

    Northwestern University · Granted Tue May 27 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8735082

    Gene signature for predicting prognosis of patients with solid tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 27 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8735066

    Tumor suppressor designated TS10Q23.3

    The Board of Regents of the University of Texas System · Granted Tue May 27 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8735358

    Methods for treating cancer by regulation of tumor necrosis factor-alpha

    The Regents of the University of Colorado, a Body Corporate · Granted Tue May 27 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. CA 3169263

    AGENTS DE TRAITEMENT DE MALADIES CANCEREUSES EXPRIMANT CLAUDINE

    TRON TRANSLATIONALALE ONKOLOGIE AN DER UNIV DER JOHANNES GUTENBERG UNIV MAINZ GEMENNUTZIGE GMBH [DE] · Granted Thu May 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8709430

    Cancer treatment kits comprising therapeutic antibody conjugates that bind to aminophospholipids

    The Board of Regents of the University of Texas System · Granted Tue Apr 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8709417

    Combination immunotherapy for the treatment of cancer

    BOARD OF REGENTS · Granted Tue Apr 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8703756

    Synthetic procedure and cancer treatment with cisplatin derivatives

    THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS · Granted Tue Apr 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8697079

    IgE antibodies for the treatment of cancer

    The Regents of the University of California · Granted Tue Apr 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8697666

    Anti-cancer oligodeoxynucleotides

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8697662

    Methods for treating Kaposi sarcoma

    PTC THERAPEUTICS, INC. · Granted Tue Apr 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8697048

    Peptide amphiphile suspension to prevent or reduce tumor formation from administered embryonic stem cells

    Northwestern University · Granted Tue Apr 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8685929

    Detecting CYP24 expression level as a marker for predisposition to cancer

    The Regents of the University of California · Granted Tue Apr 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8685416

    Compositions and methods for the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8680131

    Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers

    Jenrin Discovery, LLC · Granted Tue Mar 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8673888

    Depsipeptide for therapy of kidney cancer

    THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8663635

    N-cadherin: target for cancer diagnosis and therapy

    The Regents of the University of California · Granted Tue Mar 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8658778

    hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes

    The Board of Regents of the University of Texas System · Granted Tue Feb 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8658168

    Compositions and methods for homoconjugates of antibodies which induce growth arrest of apoptosis of tumor cells

    The Board of Regents of the University of Texas System · Granted Tue Feb 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8653283

    Anticancer agents

    The Regents of the University of California · Granted Tue Feb 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8652787

    Use of ERBB4 as a prognostic and therapeutic marker for melanoma

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8642282

    Inhibitors of nitric oxide synthase for treatment of melanoma

    The Regents of the University of California · Granted Tue Feb 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8642604

    Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents

    The Regents of the University of California · Granted Tue Feb 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8633154

    Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth

    ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Jan 21 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. EP 2678011

    ANTITUMORIGENE KOMBINATON, DIE CABAZITAXEL UND CISPLATIN UMFASST

    AVENTIS PHARMA SA [FR] · Granted Wed Jan 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Dec 27 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8618096

    Prodrug compositions and methods for using the same in treating cancer and malaria

    The Regents of the University of California · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8618058

    Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity

    Soricimed Biopharma Inc. · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8614301

    Methods of treating cancer using anti CD24 antibodies

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Tue Dec 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8614183

    Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2

    Five Prime Therapeutics, Inc. · Granted Tue Dec 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8614304

    Immunogenic peptides and methods of use for treating and preventing cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Serives · Granted Tue Dec 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8609716

    Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 17 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8609843

    Photoactive metal nitrosyls for blood pressure regulation and cancer therapy

    The Regents of the University of California · Granted Tue Dec 17 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8604023

    1,4-benzodiazepinone compounds and their use in treating cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Dec 10 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.